Clinical trials
Plasma Cell Disorder clinical trials
Below are recruiting plasma cell disorder clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT03937635RecruitingPhase 3
Lenalidomide and dexamethasone, with or without daratumumab
This phase 3 trial studies whether lenalidomide plus dexamethasone can prevent or delay progression of “high-risk smoldering” multiple myeloma, and whether adding daratumumab improves outcomes. It’s meant for people who are not yet showing symptoms, but whose lab and scan results suggest higher risk.
Birmingham, AlabamaAges 18 years+ - NCT04643002RecruitingPhase 1/Phase 2
Isatuximab added to other drugs for relapsed myeloma
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT04776395RecruitingPhase 2
Iberdomide to treat intermediate or high-risk smoldering myeloma
This Phase 2 study tests iberdomide alone or with low-dose dexamethasone in people with intermediate- or high-risk “smoldering” multiple myeloma. The goal is to see if the treatment can control or delay progression to active myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT05136807Recruiting
Quality of life study for people with MGUS or smoldering myeloma
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
Houston, TexasAges 18 years+ - NCT07179679RecruitingPhase 1
Study of a new shot for multiple myeloma
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT02726750Recruiting
Study of early plasma cell blood conditions before myeloma
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
Houston, TexasAges 18 years+ - NCT04691622RecruitingPhase 1
Treat chronic norovirus using donor immune cells
This Phase 1 study tests whether giving immune cells made from a donor can help children and adults with long-lasting (chronic) norovirus infection. It’s aimed at people whose immune system is weakened after a stem cell transplant, solid organ transplant, or due to primary immune problems.
Washington D.C., District of ColumbiaAges 3 months–80 years - NCT00067054Recruiting
Collecting blood and samples for research
This study collects blood and other samples from healthy volunteers, children, and people with infectious diseases to help advance research. If you join, you may donate blood, urine, or skin samples that will be stored and used in future studies.
Bethesda, MarylandAges 3 years+ - NCT07257029RecruitingPhase 2
Ketotifen Cream for Vulvar Pain
This trial tests a topical cream called ketotifen for treating a type of vulvar pain (secondary provoked vestibulodynia). The cream may help reduce pain at the vaginal opening, and you would apply it daily for several months.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07429253RecruitingPhase 1/Phase 2
Secretome vs. PRP for male and female hair loss
This trial compares two treatments—secretome and platelet-rich plasma (PRP)—to see which helps grow thicker, denser hair in people with genetic hair loss (androgenetic alopecia). It's for adults aged 25 to 59 who have stopped taking certain hair loss medications for at least a month.
Denpasar, BaliAges 25–59 - NCT04197596RecruitingPhase 1/Phase 2
BK infection immune-cell treatment after transplant or weak immunity
This Phase 1/2 study tests lab-made immune cells that specifically target BK virus in people whose BK infection keeps coming back or doesn’t improve. It may help by boosting the body’s ability to clear the virus, especially when standard antiviral treatments don’t work or can’t be tolerated.
San Francisco, CaliforniaAges 1 month–79 years - NCT04398628Recruiting
Study of non-cancer blood disorders in people with bleeding or clotting
This study follows people with inherited or acquired non-cancer blood disorders to better understand symptoms, causes, and how different treatments work over time. You may be placed into a disorder-specific group, depending on your diagnosis and testing results.
Phoenix, ArizonaAges Any age - NCT06414889RecruitingPhase 1
Collecting stem cells safely in RUNX1 platelet disorder
This study tests the safety of collecting your own blood stem cells (called CD34+ cells) using a process called apheresis. It is for people with RUNX1 familial platelet disorder who may need a stem cell transplant in the future.
Houston, TexasAges 18–75 - NCT02844751RecruitingPhase 2
Regenerative knee cell therapy for arthritis pain and swelling
This Phase 2 study tests a patient’s own (autologous) regenerative cell treatment to reduce knee pain and inflammation from osteoarthritis. It mainly looks at whether the treatment is safe and whether it can improve symptoms over time.
Grove City, PennsylvaniaAges 18–90 - NCT02844738RecruitingPhase 2
Cell therapy for shoulder osteoarthritis pain and inflammation
This trial tests a treatment using your own (autologous) regenerative cells to reduce pain and inflammation from shoulder osteoarthritis. It may help people with long-lasting shoulder pain, but you must meet several health and medication timing requirements.
Grove City, PennsylvaniaAges 18–90 - NCT02844764RecruitingPhase 2
Cell therapy test for hip osteoarthritis pain and swelling
This trial tests an “autologous” regenerative cell treatment, meaning cells taken from you, to reduce hip osteoarthritis pain and inflammation. It checks safety first and looks for improvements in how you feel and move.
Grove City, PennsylvaniaAges 18–90 - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07358013Recruiting
Endothelial cells in von Willebrand disease and related conditions
This study looks at special cells from blood vessels (endothelial colony-forming cells) in people with von Willebrand disease (a bleeding disorder) or a related acquired condition. The goal is to better understand these conditions using blood donations.
MilanAges 16 years+
Hear when a new Plasma Cell Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for plasma cell disorder?
- Yes. Clin2 currently lists 44 recruiting plasma cell disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a plasma cell disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a plasma cell disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.